Search company, investor...

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Series A | Alive

About Boen Ruier

Provider of wound repair biomaterials for rapid hemostasis, wound repair, and guided tissue regeneration.

Boen Ruier Headquarters Location

Xiaolan Economic & Technological Zone 266 Huiren Avenue, Block 4

Nanchang, Jiangxi, 330052,


86 13521516805

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Boen Ruier

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Boen Ruier is included in 2 Expert Collections, including Medical Devices.


Medical Devices

8,487 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health IT

7,901 items

  • Where is Boen Ruier's headquarters?

    Boen Ruier's headquarters is located at Xiaolan Economic & Technological Zone, Nanchang.

  • What is Boen Ruier's latest funding round?

    Boen Ruier's latest funding round is Series A.

  • Who are the investors of Boen Ruier?

    Investors of Boen Ruier include bioVENTURE and Silver Increscence Capital.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.